date,text,form,accepted_time
2020-04-09," 8-k/a 1 tm2015582d1_8ka.htm form 8-k/a united states securities and exchange commission washington, d.c. 20549 form 8-k/a current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 march 20, 2020 date of report (date of earliest event reported) lifesci acquisition corp (exact name of registrant as specified in its charter) delaware 001-39244 83-3197402 (state or other jurisdiction of incorporation) (commission file number) (i.r.s. employer identification no.) 250 w. 55th st., #3401 new york, ny 10019 (address of principal executive offices) (zip code) registrant’s telephone number, including area code: (646) 889-1200 n/a (former name or former address, if changed since last report) check the appropriate box below if the form 8-k filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ¨ written communications pursuant to rule 425 under the securities act ¨ soliciting material pursuant to rule 14a-12 under the exchange act ¨ pre-commencement communications pursuant to rule 14d-2(b) under the exchange act ¨ pre-commencement communications pursuant to rule 13e-4(c) under the exchange act securities registered pursuant to section 12(b) of the act: title of each class trading symbol(s) name of each exchange on which registered common stock lsac the nasdaq stock market llc warrants lsacw the nasdaq stock market llc units lsacu the nasdaq stock market llc indicate by check mark whether the registrant is an emerging growth company as defined in rule 405 of the securities act of 1933 (17 cfr §230.405) or rule 12b-2 of the securities exchange act of 1934 (17 cfr §240.12b-2). emerging growth company x if an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the exchange act. ¨ explanatory note this form 8-k/a is filed as an amendment (amendment no. 1) to the current report on form 8-k filed by lifesci acquisition corp.. on march 26, 2020. amendment no. 1 is being filed to correct an error in item 8.01 regarding the description of the private placement (as defined below). item 3.02. unregistered sales of equity securities. the information included in item 8.01 is incorporated into this item by reference. item 8.01. other events as previously disclosed on a current report on form 8-k dated march 10, 2020, lifesci acquisition corp. (the “company”), consummated its initial public offering (“ipo”) of 6,000,000 units (the “units”). each unit consists of one share of common stock, $0.0001 par value (“common stock”) and one warrant (“warrant”) entitling its holder to purchase one-half of one share of common stock at a price of $11.50 per whole share. the units were sold at an offering price of $10.00 per unit, generating gross proceeds of $60,000,000. the company granted the underwriters a 45-day option to purchase up to 900,000 additional units to cover over-allotments, if any. as also previously disclosed in the current report, simultaneously with the closing of the ipo, the company consummated the private placement (“private placement”) of 2,570,000 warrants (the “private warrants”) at a price of $0.50 per private warrant, generating total proceeds of $1,285,000. subsequently, on march 18, 2020, the underwriters exercised the over-allotment option in part, and the closing of the issuance and sale of the additional units occurred (the “over-allotment option units”) on march 20, 2020. the total aggregate issuance by the company of 563,767 units at a price of $10.00 per unit resulted in total gross proceeds of $5,637,670. on march 20, 2020, the underwriters canceled the remainder of the over-allotment option. in connection with the cancellation of the remainder of the over-allotment option, the company has canceled an aggregate of 84,058 shares of common stock issued to lifesci investments, llc, the company’s sponsor, prior to the ipo and private placement. a total of $65,637,670 of the net proceeds from the sale of units in the initial public offering (including the over-allotment option units) and the private placement on march 10, 2020 and march 20, 2020, were placed in a trust account established for the benefit of the company’s public shareholders. included with this report as exhibit 99.1 is a pro-forma balance sheet reflecting the exercise of the over-allotment option. item 9.01. financial statements and exhibits. exhibit no. description 99.1* pro-forma balance sheet dated march 20, 2020 * previously filed. signatures pursuant to the requirements of the securities exchange act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. dated: april 9, 2020 lifesci acquisition corp. by: /s/ andrew mcdonald name: andrew mcdonald title: chief executive officer ",8-K,2020-04-09 21:08:58
2020-03-25," 8-k 1 tm2013761d1_8k.htm form 8-k united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 march 20, 2020 date of report (date of earliest event reported) lifesci acquisition corp (exact name of registrant as specified in its charter) delaware 001-39244 83-3197402 (state or other jurisdiction of incorporation) (commission file number) (i.r.s. employer identification no.) 250 w. 55th st., #3401 new york, ny 10019 (address of principal executive offices) (zip code) registrant’s telephone number, including area code: (646) 889-1200 n/a (former name or former address, if changed since last report) check the appropriate box below if the form 8-k filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ¨written communications pursuant to rule 425 under the securities act ¨soliciting material pursuant to rule 14a-12 under the exchange act ¨pre-commencement communications pursuant to rule 14d-2(b) under the exchange act ¨pre-commencement communications pursuant to rule 13e-4(c) under the exchange act securities registered pursuant to section 12(b) of the act: title of each class trading symbol(s) name of each exchange on which registered common stock lsac the nasdaq stock market llc warrants lsacw the nasdaq stock market llc units lsacu the nasdaq stock market llc indicate by check mark whether the registrant is an emerging growth company as defined in rule 405 of the securities act of 1933 (17 cfr §230.405) or rule 12b-2 of the securities exchange act of 1934 (17 cfr §240.12b-2). emerging growth company x if an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the exchange act. ¨ item 3.02. unregistered sales of equity securities. the information included in item 8.01 is incorporated into this item by reference. item 8.01. other events as previously disclosed on a current report on form 8-k dated march 10, 2020, lifesci acquisition corp. (the “company”), consummated its initial public offering (“ipo”) of 6,000,000 units (the “units”). each unit consists of one share of common stock, $0.0001 par value (“common stock”) and one warrant (“warrant”) entitling its holder to purchase one-half of one share of common stock at a price of $11.50 per whole share. the units were sold at an offering price of $10.00 per unit, generating gross proceeds of $60,000,000. the company granted the underwriters a 45-day option to purchase up to 900,000 additional units to cover over-allotments, if any. as also previously disclosed in the current report, simultaneously with the closing of the ipo, the company consummated the private placement (“private placement”) of 2,570,000 units (the “private units”) at a price of $10.00 per private unit, generating total proceeds of $1,285,000. subsequently, on march 18, 2020, the underwriters exercised the over-allotment option in part, and the closing of the issuance and sale of the additional units occurred (the “over-allotment option units”) on march 20, 2020. the total aggregate issuance by the company of 563,767 units at a price of $10.00 per unit resulted in total gross proceeds of $5,637,670. on march 20, 2020, the underwriters canceled the remainder of the over-allotment option. in connection with the cancellation of the remainder of the over-allotment option, the company has canceled an aggregate of 84,058 shares of common stock issued to lifesci investments, llc, the company’s sponsor, prior to the ipo and private placement. a total of $65,637,670 of the net proceeds from the sale of units in the initial public offering (including the over-allotment option units) and the private placements on march 10, 2020 and march 20, 2020, were placed in a trust account established for the benefit of the company’s public shareholders. included with this report as exhibit 99.1 is a pro-forma balance sheet reflecting the exercise of the over-allotment option. item 9.01. financial statements and exhibits. exhibit no. description 99.1 pro-forma balance sheet dated march 20, 2020 signatures pursuant to the requirements of the securities exchange act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. dated: march 25, 2020 lifesci acquisition corp. by: /s/ andrew mcdonald name: andrew mcdonald title: chief executive officer ",8-K,2020-03-25 17:38:51
2020-03-16," 8-k 1 tm2012857d1_8k.htm form 8-k united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 march 10, 2020 date of report (date of earliest event reported) lifesci acquisition corp. (exact name of registrant as specified in its charter) delaware 001-39244 83-3197402 (state or other jurisdiction of incorporation) (commission file number) (i.r.s. employer identification no.) 250 w. 55th st., #3401 new york, ny 10019 (address of principal executive offices) (zip code) registrant’s telephone number, including area code: (646) 889-1200 n/a (former name or former address, if changed since last report) check the appropriate box below if the form 8-k filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ¨written communications pursuant to rule 425 under the securities act ¨soliciting material pursuant to rule 14a-12 under the exchange act ¨pre-commencement communications pursuant to rule 14d-2(b) under the exchange act ¨pre-commencement communications pursuant to rule 13e-4(c) under the exchange act securities registered pursuant to section 12(b) of the act: title of each class trading symbol(s) name of each exchange on which registered common stock lsac the nasdaq stock market llc warrants lsacw the nasdaq stock market llc units lsacu the nasdaq stock market llc indicate by check mark whether the registrant is an emerging growth company as defined in rule 405 of the securities act of 1933 (17 cfr §230.405) or rule 12b-2 of the securities exchange act of 1934 (17 cfr §240.12b-2). emerging growth company x if an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the exchange act. ¨ item 8.01. other events as previously disclosed on a current report on form 8-k dated march 5, 2020, on march 10, 2020 lifesci acquisition corp. (the “company”) consummated its initial public offering (“ipo”) of 6,000,000 units (the “units”). each unit consists of one share of common stock, par value $0.0001 per share (“common stock”) and one warrant (“warrant”) entitling its holder to purchase one-half of one share of common stock at a price of $11.50 per whole share. the units were sold at an offering price of $10.00 per unit, generating gross proceeds of $60,000,000. as of march 10, 2020, a total of $60,000,000 of the net proceeds from the ipo and the private placement consummated simultaneously with the closing of the ipo were deposited in a trust account established for the benefit of the company’s public stockholders. an audited balance sheet as of march 10, 2020 reflecting receipt of the proceeds upon consummation of the ipo and the private placement is included with this report as exhibit 99.1 item 9.01. financial statements and exhibits. exhibit no. description 99.1 balance sheet dated march 10, 2020 signatures pursuant to the requirements of the securities exchange act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. dated: march 16, 2020 lifesci acquisition corp. by: 	/s/ andrew mcdonald 	 name: andrew mcdonald title: chief executive officer ",8-K,2020-03-16 17:07:42
2020-03-11," 8-k 1 tm2012345-1_8k.htm form 8-k united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 march 5, 2020 date of report (date of earliest event reported) lifesci acquisition corp. (exact name of registrant as specified in its charter) delaware 001-39244 83-3197402 (state or other jurisdiction of incorporation) (commission file number) (i.r.s. employer identification no.) 250 w. 55th st., #3401 new york, ny 10019 (address of principal executive offices) (zip code) registrant’s telephone number, including area code: (646) 889-1200 n/a (former name or former address, if changed since last report) check the appropriate box below if the form 8-k filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ¨ written communications pursuant to rule 425 under the securities act ¨ soliciting material pursuant to rule 14a-12 under the exchange act ¨ pre-commencement communications pursuant to rule 14d-2(b) under the exchange act ¨ pre-commencement communications pursuant to rule 13e-4(c) under the exchange act indicate by check mark whether the registrant is an emerging growth company as defined in rule 405 of the securities act of 1933 (17 cfr §230.405) or rule 12b-2 of the securities exchange act of 1934 (17 cfr §240.12b-2). emerging growth company x if an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the exchange act. ¨ item 1.01. entry into a material definitive agreement. on march 5, 2020, the registration statement (file nos. 333-236466 and 333-236929) (the “registration statement”) relating to the initial public offering (“ipo”) of lifesci acquisition corp.(the “company”) was declared effective by the securities and exchange commission. in connection therewith, the company entered into the following agreements previously filed as exhibits to the registration statement: ● an underwriting agreement, dated march 5, 2020, by and between the company and chardan capital markets, llc (“chardan”), as representative of the underwriters; ● a warrant agreement, dated march 5, 2020, by and between the company and continental stock transfer & trust company; ● letter agreements, dated march 5, 2020, by and between the company’s officers, directors and shareholders; ● an investment management trust agreement, dated march 5, 2020, by and between continental stock transfer & trust company and the company; ● an administrative services agreement, dated march 5, 2020, by and between the company and lifesci capital llc; ● a subscription agreement, dated march 5, 2020, by and between the company and lifesci holdings llc; ● a subscription agreement, dated march 5, 2020, by and between the company and rosedale park, llc; ● a stock escrow agreement, dated march 5, 2020, by and among the company, continental stock transfer & trust company and each of the initial shareholders of the company; and ● a registration and stockholder rights agreement, dated march 5, 2020, by and among the company, lifesci holdings llc, rosedale park, llc and the initial shareholders of the company. on march 10, 2020, the company consummated the ipo of 6,000,000 units (the “units”). each unit consists of one share of common stock, $0.0001 par value (“common stock”), and one warrant (“warrant”) entitling its holder to purchase one-half of one share of common stock at a price of $11.50 per whole share. the units were sold at an offering price of $10.00 per unit, generating gross proceeds of $60,000,000. the company granted the underwriters a 45-day option to purchase up to 900,000 additional units to cover over-allotments, if any. as of march 10, 2020, a total of $60,000,000 of the net proceeds from the ipo and the private placement (as defined below) were deposited in a trust account established for the benefit of the company’s public shareholders. an audited balance sheet as of march 10, 2020 reflecting receipt of the proceeds upon consummation of the ipo and the private placement will be filed within 4 business days of the consummation of the ipo. item 3.02. unregistered sales of equity securities. simultaneously with the closing of the ipo, the company consummated the private placement (“private placement”) with (i) lifesci holdings llc of 1,570,000 warrants (the “private warrants”) and (ii) rosedale park, llc of 1,000,000 private warrants, each at a price of $0.50 per private warrant, generating total proceeds of $1,285,000. the private warrants are identical to the warrants sold in the ipo except that each private warrant is exercisable for one share of common stock at an exercise price of $11.50 per share, and the private warrants will be non-redeemable and may be exercised on a cashless basis, in each case so long as they continue to be held by the initial purchasers or their permitted transferees. additionally, such initial purchasers agreed not to transfer, assign or sell any of the private warrants or underlying securities (except in limited circumstances, as described in the registration statement) until the completion of the company’s initial business combination. such initial purchasers were granted certain demand and piggyback registration rights in connection with the purchase of the private warrants. 2 the private warrants were issued pursuant to section 4(a)(2) of the securities act of 1933, as amended, as the transactions did not involve a public offering. item 5.03. amendments to certificate of incorporation or bylaws; change in fiscal year. on march 5, 2020, in connection with the ipo, the company filed its amended and restated certificate of incorporation with the secretary of state of delaware. the terms of the amended and restated certificate of incorporation are set forth in the registration statement and are incorporated herein by reference. item 9.01. financial statements and exhibits. exhibit no. description 1.1 underwriting agreement, dated march 5, 2020, by and between the registrant and chardan capital markets, llc. 3.1 amended and restated certificate of incorporation 4.1 warrant agreement, dated march 5, 2020, by and between continental stock transfer & trust company and the registrant. 10.1 letter agreements, dated march 5, 2020, among the registrant and the registrant’s officers, directors and initial stockholders. 10.2 investment management trust agreement, dated march 5, 2020, by and between continental stock transfer & trust company and the registrant. 10.3 stock escrow agreement, dated march 5, 2020, among the registrant, continental stock transfer & trust company and the initial stockholders. 10.4 registration and stockholder rights agreement, dated march 5, 2020, by and between the registrant and initial stockholders. 10.5 administrative services agreement, dated march 5, 2020, by and between the registrant and lifesci capital llc. 10.6 subscription agreement, dated march 5, 2020, by and between the registrant and lifesci holdings llc. 10.7 subscription agreement, dated march 5, 2020, by and between the registrant and rosedale park, llc. 3 signatures pursuant to the requirements of the securities exchange act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. dated: march 11, 2020 lifesci acquisition corp. by: /s/ andrew mcdonald name: andrew mcdonald title: chief executive officer 4 ",8-K,2020-03-11 16:34:15
